<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1590" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="657" end="660"/>
    <type:ORR xmi:id="17" sofa="6" begin="719" end="722"/>
    <type:PFSMean xmi:id="21" sofa="6" begin="1024" end="1027"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="1036" end="1046"/>
    <type:OSMean xmi:id="29" sofa="6" begin="1205" end="1208"/>
    <type:OSMean xmi:id="33" sofa="6" begin="1216" end="1227"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="The published data on the predictive and prognostic value of KRAS mutations in&#13;&#10;metastatic colorectal cancer (mCRC) treated with cetuximab seemed inconclusive.&#13;&#10;To derive a more precise estimation of the relationship, a meta-analysis was&#13;&#10;performed. Systematic computerised searches of the PubMed, EMBase, BIOSIS, and&#13;&#10;SCOPUS were performed. A total of 22 studies were identified. Random-effects&#13;&#10;model or fix-effects model was used according to between-study heterogeneity. A&#13;&#10;total of 2188 mCRC patients were included in the final meta-analysis. The rate of&#13;&#10;KRAS mutations was 38% (829/2188). The overall response rate (ORR) of mutant KRAS&#13;&#10;patients was 14% (119/829), whereas the ORR of wild-type KRAS patients was 39%&#13;&#10;(529/1359). The overall pooled relative ratio (RR) for ORR was 0.24 (95%&#13;&#10;confidence intervals (CI): 0.16-0.38; P&lt;0.01) when mutant KRAS patients were&#13;&#10;compared with wild-type KRAS patients. Median PFS was significantly shorter in&#13;&#10;mutant KRAS patients compared with that in wild-type KRAS patients (3.0 versus&#13;&#10;5.8 months; HR=1.94; 95% CI: 1.62-2.33; P&lt;0.01). Similarly, median OS was&#13;&#10;significantly shorter in mutant KRAS patients compared with that in wild-type&#13;&#10;KRAS patients (6.9 versus 13.5 months; HR=2.17; 95% CI: 1.72-2.74; P&lt;0.01). The&#13;&#10;meta-analysis strongly suggests that KRAS mutations represent adverse predictive &#13;&#10;and prognostic biomarkers for tumour response and survival in mCRC patients&#13;&#10;treated with cetuximab. Patients with tumours that harbour mutant-type KRAS are&#13;&#10;more likely to have a worse response, PFS, and OS when treated with cetuximab."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33"/>
</xmi:XMI>
